Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

In preclinical animal trials, third-party testing results showed that AIM Vaccine's mRNA RSV vaccine achieved significantly ...

We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before ...

is an mRNA-based vaccine that sends signals to your cells to produce the same protein F that causes the immune reaction that fights against RSV. These vaccines are recommended and available for ...

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

The company’s latest RSV vaccine is yet to show promising sales. This has weighed on MRNA stock, down 52% since early 2024. Even if we look at a slightly longer period, the changes in MRNA stock ...

A research team from POSTECH has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.

designed to protect against RSV and COVID-19. Beyond vaccines, pharma is looking to develop mRNA vaccines to treat diseases requiring protein expression, such as cancer. Cancer has proved to be a ...

In November 2024, Moderna gained approval from Health Canada for its mRNA vaccine, mRESVIA, aimed at preventing lower respiratory tract disease caused by the respiratory syncytial virus in those aged ...

The bill would implement a moratorium for a decade. “I am not against vaccination in any way,” the freshman lawmaker said.

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely ...

HONG KONG SAR - Media OutReach Newswire – 5 February 2025 - AIM Vaccine Co., Ltd. (06660), a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory ...